LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

LLY

1,037

+2.17%↑

JNJ

244.47

+1.48%↑

ABBV

227.53

+3.09%↑

NVS

160.86

+0.83%↑

MRK

119.17

-0.13%↓

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

1.19 1.71

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.1400000000000001

Maxim

1.19

Indicatori cheie
By Trading Economics
Venit	1.8M -32M
Vânzări	-166K 1.7M
Marjă de profit	-1,852.384
Angajați	181
EBITDA	7.9M -29M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+335.71% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 mar. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	3.5M 129M
Deschiderea anterioară	-0.52
Închiderea anterioară	1.19

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 feb. 2026, 23:57 UTC

Acțiuni populare

Stocks to Watch: Applied Materials, Arista, DraftKings, Pinterest

12 feb. 2026, 23:35 UTC

Câștiguri

Principalele dinamici ale pieței

Arista Networks Surges on AI Networking Demand, Despite Rising Costs

12 feb. 2026, 23:28 UTC

Câștiguri

Applied Materials Profit Rises on Soaring AI Demand -- Update

12 feb. 2026, 21:47 UTC

Câștiguri

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

13 feb. 2026, 00:00 UTC

Market Talk

ANZ Gets a New Bull as Productivity Prospects Improve -- Market Talk

12 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After AI Concerns Drag Stocks on Wall Street -- Market Talk

12 feb. 2026, 23:38 UTC

Market Talk

Gold Steady; Could Undergo Technical Recovery -- Market Talk

12 feb. 2026, 23:33 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- 2nd Update

12 feb. 2026, 23:09 UTC

Market Talk

South32's Hermosa Review Stokes Spending Fears -- Market Talk

12 feb. 2026, 22:55 UTC

Câștiguri

Acțiuni populare

Applied Materials, DraftKings, Airbnb: Earnings in Focus -- WSJ

12 feb. 2026, 22:46 UTC

Market Talk

Northern Star Outlook Needs Project Done On Time, In Budget -- Market Talk

12 feb. 2026, 22:23 UTC

Câștiguri

Coinbase Swings to a Fourth-Quarter Loss Amid Crypto Meltdown -- Update

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines: Gold Production for 2026 and 2027, Expected at 3.3M to 3.5M Ounces Annually, Is Consistent With Previous Guidance, With Offsetting Adjustments Between Mine Sites >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines Raises Dividend to 45c >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM.T

12 feb. 2026, 22:15 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

AGNICO EAGLE REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - RECORD QUARTERLY AND ANNUAL FREE CASH FLOW; 2025 PRODUCTION GUIDANCE ACHIEVED; TOTAL 2025 SHAREHOLDER RETURNS OF $1.4 BILLION; DIVIDEND INCREASED BY 12.5%; UPDATED THREE-YEAR GUIDANCE >AEM.T

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Rev $3.56B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Net $1.52B >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q Adj EPS $2.70 >AEM

12 feb. 2026, 22:00 UTC

Câștiguri

12 feb. 2026, 22:00 UTC

Câștiguri

Agnico-Eagle Mines 4Q EPS $3.04 >AEM

12 feb. 2026, 21:57 UTC

Câștiguri

XP 4Q Rev BRL4.95B >XP

12 feb. 2026, 21:52 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 feb. 2026, 21:47 UTC

Câștiguri

Morningstar 4Q Rev $641M >MORN

12 feb. 2026, 21:39 UTC

Câștiguri

Coinbase Revenue Falls Short as Crypto Market Sags -- Barrons.com

12 feb. 2026, 21:38 UTC

Câștiguri

Howmet Stock Jumps. Earnings Show Strength For This Sector. -- Barrons.com

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

335.71% sus

Prognoză pe 12 luni

Medie 4.88 USD 335.71%

Maxim 8 USD

Minim 2 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.